54 results
6-K
EX-99.1
BLU
Bellus Health Inc
29 Mar 23
Current report (foreign)
5:26pm
2a RELIEF trial, and seeks compensatory damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other … as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16, 2021, Plaintiff stipulated to dismissal of all claims
6-K
EX-99.1
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16
6-K
EX-99.2
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
RELIEF trial, and seeks compensatory damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other reasonable
6-K
EX-99.1
BLU
Bellus Health Inc
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
) CHEST 153 (1): 196 - 209. 2. Kuzniar et al. (2007) Mayo Clin. Proc. 82(1) 56 - 60. 3. Ryan NM, (2018) Expert Opin Pharmacother 19(7): 687 - 711. 4
6-K
EX-99.1
BLU
Bellus Health Inc
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
interest, as well as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16, 2021, Plaintiff stipulated to dismissal
6-K
EX-99.2
sjzm4i6gkkcqxg47l
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
4yhrv9q4s5k40q hdzm
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.2
gtq m1ddcdd3r1r0f
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
rnd55id
5 Apr 22
Current report (foreign)
4:07pm
40-F
w57 farssst
23 Feb 22
Annual report (Canada)
5:20pm
40-F
EX-99.1
pwe9bo1fh ucp3c
23 Feb 22
Annual report (Canada)
5:20pm
40-F
EX-99.3
x7y4238 5mnmw5
23 Feb 22
Annual report (Canada)
5:20pm
40-F
EX-99.2
uvxub6d
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.2
h7adcz2 6gmo
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.2
rav0bboztkwh u8
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.1
t9a eif1c
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.1
kboa nxavs
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
6-K
EX-99.2
gpa0oityab4uayfbtio
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
6-K
EX-99.2
yejxy0kf0
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
6-K
EX-99.1
52101alnf9ot4tbu8
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm